Monoclonal antibody therapy is a new treatment strategy for many types of diseases including cancers and autoimmune diseases, realizing a high efficacy and tolerability. In multiple sclerosis (MS) and neuromyelitis optica (NMO) spectrum disorders, several monoclonal antibodies have been suggested to decrease the incidence of clinical relapse and the disease activity. In MS, anti-α4 integrin (natalizumab), anti-CD52 (alemtuzumab), anti-CD25 (daclizumab) and anti-CD20 (ocrelizumab) have been shown to effectively reduce the relapses in randomized controlled trials and have been approved by the Food and Drug Administration. Specifically, ocrelizumab is the first drug that has shown significant suppression of brain volume loss and suppression of chronic disability progression. In NMO, though there have yet to be any approved monoclonal antibodies, rituximab, anti-complement C5 (eculizumab), anti-IL-6 receptor (tocilizumab), anti-CD19 (inebilizumab) and non-pathogenic anti-aquaporin 4 (aquaporumab) have been suggested to be effective, and some of these are now under clinical trials. Aquaporumab is a non-pathogenic recombinant human monoclonal antibody that competitively inhibits the binding of the pathogenic auto-antibody against aquaporin 4 in NMO patients; thus, it is expected to be highly disease specific with less non-specific adverse events. Some of these monoclonal antibodies in MS and NMO are known to cause several notable adverse events. Natalizumab and rituximab increase the risk of progressive multifocal leukoencephalopathy. Eculizumab increases the risk of meningococcal infection. Tocilizumab is known to cause intestinal diverticulitis that can cause intestinal perforation. In this review, we summarize the characteristics of, evidence for and notable adverse events of each monoclonal antibody in MS and NMO.
Introduction
Multiple sclerosis (MS) and neuromyelitis optica (NMO) spectrum disorder are two major neurological demyelinating diseases in which the effects of antibody therapy have been established.
MS is a disease that damages oligodendrocytes in the central nervous system (CNS) for unknown reasons and causes the development of multiple demyelinating lesions in optic nerves, the cerebrum, brain stem, cerebellum and spinal cord. MS mostly occurs in young females with an onset age below 50 years. Diagnosis of MS is essentially made by the dissemination of CNS lesions in time and space (1, 2) . NMO is another disease that mainly damages astrocytes of the CNS in association with a serum auto-antibody against aquaporin 4 (AQP4-Ab) (3) . Patients with NMO more predominantly show lesions in optic nerves and the spinal cord and the rate of affected females is much higher than that in MS. Eventual disability levels after optic neuritis and spinal cord lesions are likely to be more severe in NMO than in MS. Characteristic lesions in AQP4-Ab + NMO are optic chiasmal lesions and longitudinally extensive spinal cord lesions (4) (5) (6) (7) .
Recently, serum auto-antibody against the myelin oligodendrocyte glycoprotein (MOG-Ab) has been shown to be present in some of those previously diagnosed with MS, NMO or acute disseminated encephalomyelitis (8) (9) (10) . Those with serum MOG-Ab are known to come from a different demographic background and have a distinct clinical phenotype from the others, so have gradually been regarded as a different disease entity (11) (12) (13) . On the basis of these facts, neurologists now usually categorize patients with demyelinating diseases into MS, AQP4-Ab + NMO and others (including patients with serum MOG-Ab). MS is further categorized into relapsing-remitting MS, primary progressive MS and secondary progressive MS (14) . In this review, the term 'MS' represents relapsing-remitting MS for convenience unless otherwise mentioned.
Treatments in the acute phase of all of the above-mentioned disease groups include steroid pulse therapy and/or plasmapheresis (15, 16) . Immuno-modulating therapies in the remission phase are different between MS and AQP4-Ab + NMO. The mainstream treatment in the remission phase of MS is disease-modifying drugs (DMDs), in which IFN-β, glatiramer acetate and dimethyl fumarate are commonly used as a first-line therapy (17) . The mainstream of treatment in the remission phase of AQP4-Ab + NMO is immunosuppressant drugs including oral corticosteroids, azathioprine, mycophenolate mofetil, cyclosporine or tacrolimus (18) .
In addition to these conventional relapse prevention therapies, many types of molecularly targeted therapies with monoclonal antibodies have been introduced recently ( Fig. 1) , some of which are still under clinical trials. The therapeutic goal in MS has gradually shifted from preventing clinical relapse to preventing the irreversible progression of cerebral atrophy (19) , but all of the conventional treatments for MS have failed this goal. Newly introduced monoclonal antibodies are expected to achieve this goal. In this review, we comprehensively summarize representative monoclonal antibodies that have garnered attention for the treatment of MS and NMO.
Monoclonal antibody therapies for MS
Six monoclonal antibodies for MS are described in this review. A schematic illustration of the mechanisms of these drugs is shown in Fig. 2 and a summary of the information on these drugs is listed in the upper half of Table 1 .
Natalizumab (Tysabri®)
Natalizumab is a humanized IgG4 monoclonal antibody against α4 integrin (CD49d), an adhesion molecule. This drug is one of the strongest and most established monoclonal antibody therapies for MS at present. Natalizumab blocks the binding of α4β1-integrin on the surface of lymphocytes to vascular cell adhesion molecule-1 (VCAM1) on the surface of endothelial cells and prevents the passage of inflammatory immune cells (mainly T cells) through the gut and blood-brain barrier (20, 21) . The main target diseases of natalizumab are MS and Crohn's disease. Natalizumab is usually administered intravenously once for 4 weeks.
Natalizumab was shown to be effective for suppressing the relapse rate and the advent of new lesions detectable by magnetic resonance imaging (MRI) in randomized placebocontrolled trials (22, 23) . Natalizumab was also shown to be effective for suppressing the relapse rate and progression of disability in patients with MS who were refractory to IFN-β1a (24) . However, natalizumab was not effective at suppressing the progressive cerebral atrophy (25) . The mechanism by which natalizumab suppresses not only the occurrence of relapse but also the progressive degenerative process is unknown, but we can estimate that the irreversible axonal damage secondary to demyelination in MS may be alleviated by natalizumab.
The most infamous and lethal adverse event of natalizumab is progressive multifocal leukoencephalopathy (PML), especially in patients who are positive for the John Cunningham virus (JCV) antibody. Specific diagnosis of PML is aided by PCR of JCV DNA in the cerebrospinal fluid (26) . The occurrence of PML in patients with natalizumab is estimated to be >1 in 1000, which is >100 times higher than that in the normal population. In patients who are positive for the JCV antibody, the risk of PML increases as the duration of the drug increases; the risk increases dramatically if the duration of natalizumab treatment exceeds 2 years (27) . Checking for positivity for the JCV antibody before starting natalizumab treatment is indispensable.
It should be noted that the risk of PML further increases in those patients who have been treated with immune-suppressive treatments such as azathioprine and mitoxantrone before starting natalizumab (28) . Another concern related to natalizumab is the rebound effect after discontinuing the drug, which could result in an even worse disease condition than that before starting natalizumab (29, 30) . Considering these facts together, avoiding natalizumab treatment in patients positive for the JCV antibody is safe. Lastly, natalizumab has the potential to exacerbate the disease activity in NMO (31); therefore, accurate discrimination of MS and NMO before starting natalizumab is essential.
Alemtuzumab (Campath®/Lemtrada®)
Alemtuzumab is a humanized IgG1 monoclonal antibody against CD52, which is expressed on the surface of many types of immune cells and sperm cells. Though the exact role of CD52 is not fully known, CD52 is speculated to be important for enabling lymphocytes to move freely by working as an anti-adhesion molecule (32) . The exact physiological mechanism of alemtuzumab is unknown, but the drug destroys these CD52-expressing lymphocytes. Because the IgG subclass of alemtuzumab is IgG1, this drug causes both antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) on the target. Alemtuzumab is administered intravenously every other day; promising target diseases of this drug are chronic lymphocytic leukemia and MS. There are several non-randomized longitudinal studies that showed that alemtuzumab decreases the relapse rate in MS (33) (34) (35) . Additionally, there have been several randomized active-control trials showing that alemtuzumab is superior to IFN-β for suppressing the relapse rate (36) (37) (38) (39) . Whether the drug has the long-term effects of preventing degenerative cerebral atrophy is still unsettled.
Major adverse events of alemtuzumab are infusion-related reactions (>90%) and infections (60-80%). A mild increase in the risk of autoimmune thyroid disease is also known as an adverse event of alemtuzumab (40) . Although CD52 is widely expressed on sperm cells, there has been no report mentioning an adverse event on sperm quality or infertility.
Daclizumab (Zinbryta®)
Daclizumab is a humanized IgG1 monoclonal antibody against CD25, which is the α-subunit of the IL-2 receptor expressed on many types of lymphocytes. Lymphocytes expressing both CD4 and CD25 are known as T reg cells, which suppress NK cell-mediated cytotoxicity in normal conditions (41) . By blocking CD25, this drug causes the relative expansion of immune-regulatory NK cells compared with other lymphocytes and is thought to decrease the formation of MS plaques in the brain (42) . The drug is administered subcutaneously once every 4 weeks.
Daclizumab, either in a medium dose or a high dose, was shown to reduce the relapse rate in MS by ~50% compared with placebo; the rate of patients who were relapse free was also higher in the daclizumab group (43) . Recently, two randomized active-control double-blind trials comparing daclizumab with IFN-β showed that daclizumab was superior to IFN-β in reducing the relapse rate and the new advent of MRI-detectable lesions (44, 45) . However, daclizumab was not superior to IFN-β in suppressing the long-term progressive neurological disability.
Major adverse events of daclizumab are infusion-related reactions and infections, as with other monoclonal antibodies. Daclizumab could cause severe liver complications in some patients; thus, the drug should be avoided in patients with hepatic diseases (46) .
Rituximab (Rituxan®)
Rituximab is a chimeric IgG1 monoclonal antibody against CD20, which is expressed on the surface of B cells at a wide range of maturation stages except for pre-B cells and plasma cells. Although the exact function of CD20 is unknown, it is believed to suppress apoptotic death of CD20-expressing B cells in normal conditions. Rituximab induces both apoptotic and cytotoxic (ADCC and CDC) cell death in CD20-expressing B cells. Rituximab is usually administered intravenously at 375 mg m −2 body surface per day weekly for 4 weeks as a loading dose (47) . It can also be loaded at 1000 mg per day once every 2 weeks for a total of two doses (48) . An additional dose can be given 6-9 months after the previous infusion depending on the degree of recovery of blood B-cell levels.
Rituximab for patients with MS or NMO is an off-label use at present, but there are some promising reports that mention the effectiveness of rituximab in refractory cases. In this section, we describe the effectiveness of rituximab for MS, and the effectiveness for NMO will be discussed in a later section.
There was a randomized double-blind controlled trial that showed the effectiveness of rituximab in reducing the relapse rate and volume of MRI lesions in relapsing-remitting MS (49) . In primary progressive MS, there was a randomized controlled trial that showed that rituximab reduced the MRI lesion volume more than placebo (50) . In this report, the progression of neurological disability, measured with the Expanded Disability Status Scale (EDSS), was not significantly decreased with rituximab but was suggested to be milder in younger patients. Though there has not been a randomized blinded active-control trial comparing rituximab with other DMDs in MS, there has been a report suggesting that rituximab is superior to fingolimod in suppressing relapses and the new advent of active MRI-detectable lesions in relapsing-remitting MS after the cessation of natalizumab because of the risk of PML (51) .
Major adverse events of rituximab include infusion-related reactions and infections, as with other monoclonal antibodies. There might be a slight risk of PML in patients treated with rituximab, although there have been no reports of rituximab increasing PML risk in MS patients (52) . At present, there has been no report of MS patients presenting PML with rituximab, but it would be better to check for JCV positivity before starting rituximab treatment. Another important adverse event of rituximab is reactivation of hepatitis B virus, which could result in severe hepatic failure (53) . Thus, checking for serum positivity for the hepatitis B virus antigen would also be desirable before starting rituximab.
Ocrelizumab (Ocrevus®)
Ocrelizumab is a humanized IgG1 monoclonal antibody against CD20, the same target molecule for rituximab and ofatumumab. Because ocrelizumab contains more humanderived polypeptides than rituximab does, ocrelizumab is expected to have less risk of allergic reactions or the occurrence of a neutralizing antibody response than rituximab. This drug is usually administered intravenously once every 24 weeks for 96 weeks.
Recently, a randomized active-control study comparing the effectiveness of ocrelizumab and IFN-β in relapsing-remitting MS has been reported (54) . Ocrelizumab was superior to IFN-β in suppressing the relapse rate and new advent of active MRI-detectable lesions. In addition, in this report, the progression of disability at 12 and 24 weeks from starting the treatments was suggested to be milder in the ocrelizumabtreated group than in the IFN-β-treated group. Among all existing drugs for MS, ocrelizumab is the first drug that has shown statistically significant suppression of progressive neurological disability. Ocrelizumab has also shown to be effective in primary progressive MS. In a randomized controlled study on primary progressive MS, ocrelizumab was superior to placebo in reducing the relapse rate, MRI-detected lesion volume and rate of brain volume loss (55) . Considering these results together, we can say that ocrelizumab is the first drug to show evidence of suppressing the irreversible progression of neurological disability and brain atrophy in MS.
Major adverse events have included infusion-related reactions and infections, but the rate of infusion-related reactions was estimated to be 30-40%, which is relatively low for a monoclonal antibody (54) . Additionally, the rate of serious adverse events was suggested not to be higher in the ocrelizumab-treated group than in the placebo-treated group (55).
In conclusion, ocrelizumab is one of the most effective and tolerable monoclonal antibodies in the treatment of MS.
Ofatumumab (Arzerra®)
Ofatumumab is a fully human IgG1 monoclonal antibody against CD20, the same target molecule for rituximab and ocrelizumab. Because the polypeptides of this drug are completely derived from humans, the rate of allergic reactions and the advent of neutralizing antibodies are expected to be the lowest among the monoclonal antibodies. As of 2016, this drug is only approved for chronic lymphocytic leukemia. This drug is usually administered intravenously once weekly for the first eight doses and once every 4 weeks for another four doses. A subcutaneous formulation of ofatumumab is now under investigation to achieve a slower absorption, and the route of administration may be changed in the future (56) .
There has been no clinical trial studying the effectiveness of ofatumumab in MS and the drug is still at an experimental stage in the treatment of the disease. However, because of its expected high safety and tolerability, this drug may be one of the choices for the treatment of MS in the future.
Major adverse events of ofatumumab are infusion-related reactions and infections, as with other monoclonal antibodies.
The risk of reactivation of hepatitis B virus, which can cause liver failure, is also known.
Monoclonal antibody therapies for AQP4-Ab + NMO
Five monoclonal antibodies for NMO are described in this paper. A schematic illustration of the mechanisms of these drugs is shown in Fig. 3 and a summary of the information for these drugs is listed in the lower half of Table 1 .
Rituximab (Rituxan®)
An overview of rituximab was already described in a previous section. Therefore, in this section, the clinical effectiveness of rituximab in NMO will be the focus. There has been one retrospective longitudinal comparison study comparing the relapse rate before and after starting rituximab in NMO patients (57) . In this report, the relapse rate was significantly reduced after starting rituximab compared with before starting the drug and the progression of disability was stabilized in 20 of the 25 patients. Although the clinical evidence for rituximab treatment in NMO has not yet been established, the drug is one of the promising second-line alternative treatments; further clinical trials are needed to establish the evidence.
Eculizumab (Soliris®)
Eculizumab is a humanized IgG2/IgG4-hybrid monoclonal antibody against C5 (complement component 5), which is a fundamental molecule for assembling the end-product called the C5b6789 complex. The C5b6789 complex is also known as the membrane-attack complex, which shows a very strong ability to destroy the membrane of target cells. Eculizumab blocks the cleavage of C5 into C5a and C5b, resulting in the blockade of C5b6789 complex assembly. Blockade of the C5b6789 complex mitigates the destruction Fig. 3 . Mechanisms of therapeutic monoclonal antibodies used in NMO spectrum disorder patients who have pathogenic serum AQP4-Ab. These monoclonal antibodies are certainly promising therapeutic targets, but none of them have been approved for treatment of NMO as of 2016. Additionally, none of these drugs have been shown to be effective in a randomized controlled trial before. Clinical trials are needed before these drugs will be approved in the future. Different from other drugs, aquaporumab shows its effect by competitively inhibiting the binding of the pathogenic AQP4-Ab in patients.
of systemic tissue cells and red blood cells; thus, this drug has been approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Though still at an experimental stage, this drug is also expected to be effective in other autoimmune diseases including NMO. Eculizumab is usually administered intravenously once weekly for the first 5 weeks and once every 2 weeks thereafter.
There was an open-label longitudinal study that suggested the effectiveness of eculizumab in reducing relapses and alleviating the disability level in NMO (58) . At present, a randomized double-blind controlled trial (the PREVENT study) is planned and now recruiting patients. This clinical trial will determine the effectiveness of eculizumab for NMO in the future.
Major adverse events of eculizumab are infusion-related reactions and infections, as with other monoclonal antibodies. Because eculizumab inhibits the assembly of the C5b6789 complex, the risk of infection by polysaccharide encapsulated bacteria (meningococcus, pneumococcus or Haemophilus influenzae) is known to increase. Especially, severe meningococcal infection could be caused by eculizumab treatment; thus, meningococcal vaccination at least 2 weeks prior to starting eculizumab is highly recommended (59) . Also, the risk of PML is doubted to increase with eculizumab; thus, checking for the presence of the JCV antibody before starting eculizumab is recommended.
Tocilizumab (Actemra®)
Tocilizumab is a humanized IgG1 monoclonal antibody against the IL-6 receptor. IL-6 is secreted from many types of cells including lymphocytes and fibroblasts. There are two types of IL-6 receptors: a membrane-bound type and soluble type (60) . Both of these types of IL-6 receptors transmit the IL-6 signal, which eventually activates expression of some genes. The physiological actions of IL-6 are as follows: increasing chemokine secretion, increasing the expression of adhesion molecules, facilitating the differentiation of B cells into plasma cells, suppressing the activity of T reg cells and facilitating the differentiation of T cells into T h 17 cells (60) (61) (62) (63) . Tocilizumab blocks these IL-6-mediated immunological actions. Because the level of IL-6 in cerebrospinal fluid is significantly higher in NMO patients, tocilizumab has recently been expected to be one of the possible treatment strategies for NMO. Tocilizumab is usually administered intravenously once every 4 weeks. It can also be administered subcutaneously, with both routes showing similar efficiency (64) .
There have been some case reports showing that tocilizumab significantly decreases the relapse rate and possibly decreases the neurological disability level in NMO (65) (66) (67) (68) (69) (70) . Most of these reports suggest that tocilizumab could be a highly effective alternative second-line treatment in cases in which other first-line treatments have failed to stabilize the disease condition of NMO, necessitating a change in treatment. At present, there has been no ongoing randomized controlled clinical trial of tocilizumab in NMO, but this drug may be one of the promising second-line alternative treatments in NMO. The application should be deliberately determined, balancing the risks and benefits in each case.
Major adverse events of tocilizumab are infusion-related reactions and infections, as with other monoclonal antibodies.
There has been a case report mentioning the possibility that tocilizumab treatment for rheumatoid arthritis could trigger the onset of some autoimmune neurological disorders such as MS (71) . Another critical adverse event of tocilizumab is the occurrence of multiple colon ulcers and diverticulitis, which can result in intestinal perforation (72, 73) . Tocilizumab is also known to cause an elevation of serum cholesterol levels (74) .
Inebilizumab (MEDI-551)
Inebilizumab is a humanized IgG1 monoclonal antibody against CD19, which is expressed on B cells in a wide range of differentiation stages before plasma cells. Inebilizumab results in depletion of B cells and is believed to be effective for B-cell-related malignancies and autoimmune diseases. This drug is now administered intravenously, but the dosing and its frequency have not been established yet. Inebilizumab is expected to be able to achieve more efficient depletion of circulating plasmablasts than other B-cell-targeted monoclonal antibodies (75) ; randomized active-control trials in the future are needed.
There has been no clinical trial or case report on the effectiveness of inebilizumab in NMO. At present, there has been no report on notable adverse events of inebilizumab other than infusion-related reactions and infections (75) .
Aquaporumab (mAb-53)
Aquaporumab is a non-pathogenic recombinant human monoclonal antibody against the AQP4 protein. Aquaporumab, just like the pathogenic AQP4-Ab, binds to the AQP4 protein with its F ab portion, but the F c portion of aquaporumab is artificially mutated to lack the potential to activate complement components (76, 77) . Thus, by the possible mechanism of competitive inhibition as a steric inhibitor, aquaporumab is expected to block the cell-and complement-mediated cytotoxicity of the pathogenic AQP4-Ab in NMO patients.
There has been no clinical application of aquaporumab in humans, but it has been suggested to be effective in a mouse model of NMO (77) . In the mouse model, administration of aquaporumab potently inhibited binding of the pathogenic AQP4-Ab to AQP4-expressing target cells and prevented the expected cytotoxicity.
The adverse events of aquaporumab in humans are not known yet because this drug is still at an experimental stage. However, if applied to NMO patients in the future, this drug is expected to show fewer adverse events because of its specific binding to the AQP4 protein with minimum effects on the physiologic balance of the immune system.
Pregnancy
Monoclonal antibody therapies are not contraindicated in pregnant women and are not considered to increase the rate of miscarriage at present. However, it is necessary to recognize that an IgG antibody can pass through the placenta in the third trimester of pregnancy (78, 79) . In addition, whether monoclonal antibodies increase the risk of spontaneous abortion in the first trimester of pregnancy has not yet been concluded; it is necessary to take extra precautions when administering monoclonal antibodies to pregnant women. On the other hand, aquaporumab has been suggested to decrease AQP4-Ab-mediated miscarriage and fetal death by competitively blocking the binding of the pathogenic AQP4-Ab that causes placentitis (80) . Considering these facts together, at present, usage of a monoclonal antibody in pregnancy should be deliberately considered in each case, judging the balance of the risks and benefits to the fetus.
Conclusions
Though there remains a problem of the expensive cost of monoclonal antibody therapies, we can conclude that most of the above-described monoclonal antibodies are highly effective and mostly tolerable for MS and NMO patients. Some, such as natalizumab, may be one of the first-line treatments, and others could contribute as second-line alternative treatments in refractory cases. There are many hybridized or mutated next-generation monoclonal antibodies that exhibit fewer adverse events and higher tolerability. Target molecules of monoclonal antibodies have also been more disease specific, such as aquaporumab, resulting in a higher efficiency and fewer adverse effects. Most of those monoclonal antibodies have not yet been approved for MS and NMO treatment in most countries, but their clinical applications should be deliberately and positively considered in each patient, balancing the risks and benefits.
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